Ipca Laboratories Earnings Call Transcript: Key Takeaways
Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.
Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.
Ipca Labs reports 8% FY26 consolidated revenue growth to ₹9,646cr. Management focuses on margin improvement and volume-led growth in domestic and US markets.